Approval · Notice of Compliance 20371 · 2018
GABAPENTIN: Notice of Compliance 20371
Issued January 19, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20371
- Date
- January 19, 2018
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Canadian reference product
- NEURONTIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GABAPENTIN | 02388219 | Marketed |
| GABAPENTIN | 02388200 | Marketed |
Medicinal ingredients
- GABAPENTIN 800 MG per TAB
- GABAPENTIN 600 MG per TAB